Assembly of Bio-Nanoparticles for Double Controlled Drug Release

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Huang, Wei ^a   Zhang, Jianfei ^b   Dorn, Harry C ^b   Zhang, Chenming ^a  

^a State University   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CHOLESTEROL; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOL; IMMUNOLIPOSOME; NANOPARTICLE; PACLITAXEL; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; POLYETHYLENE; SINGLE WALLED NANOTUBE;

ACIDIFICATION; ARTICLE; BODY TEMPERATURE; BREAST CANCER; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; IN VIVO STUDY; LYSOSOME; PH; THERMOSTABILITY; ZETA POTENTIAL;

CELL LINE; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; HUMANS; HYDROGEN-ION CONCENTRATION; LIPOSOMES; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; NANOCOMPOSITES; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RECEPTOR, ERBB-2; SERUM; SOLUBILITY;

EID: 84883629924     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074679     Document Type: Article

References (54)

1. Brigger I, Dubernet C, Couvreur P, (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54: 631-651.
2. Parveen S, Mistra R, Sahoo SK, (2012) Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 8: 147-166.
3. Reddy LH, (2005) Drug delivery to tumors: recent strategies. J Pharm Pharmacol 37: 1231-1242.
4. Yang T, Choi M, Cui F, Kim JS, Chung S, et al. (2007) Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 120: 169-177.
5. Ptail Y, Sadhukha T, Ma L, Panyam J, (2009) Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tarquidar overcomes tumor drug resistance. J Control Release 136: 21-29.
6. Peppas LB, (1995) Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int J Pharm 116: 1-9.
7. Dufort S, Sancey L, Coll JL, (2012) Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution. Adv Drug Deliv Rev 64: 179-189.
8. Simoes S, Slepushkin V, Duzgunes N, de Lima MCP, (2001) On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes. Biochim Biophys Acta 1515: 23-37.
9. Kang SI, Na K, Bae YH, (2003) Physicochemical characteristics and doxorubicin-release behaviors of pH/temperature-sensitive polymeric nanoparticles. Colloids Surf A Physicochem Eng Asp 231: 103-112.
10. Xiao K, Li Y, Li JS, Xiao W, Gonik AM, et al. (2011) The effect of surface charge on in vivo biodistribution of PEG-oligocholic aid based micellar nanoparticles. Biomaterials 32: 3435-3446.
11. Kennel SJ, Woodward JD, Rondinone AJ, Wall J, Huang Y, et al. (2008) The fate of MAb-targeted Cd125mTe/ZnS nanoparticles in vivo. Nucl Med Biol 35: 501-514.
12. Fredenberg S, Wahlgren M, Reslow M, Axelsson A, (2011) The mechanisms of drug release in poly (lactic-co-glycolic acid)-based drug delivery systems-A review. Int J Pharm 415: 34-52.
13. Xu J, Yudasaka M, Kourada S, Sekido M, Yamamoto Y, et al. (2008) Single wall carbon nanohorn as a drug carrier for conrolled release. Chem Phys Lett 461: 189-192.
14. Gerweck LE, (1998) Tumor PH: Implications for treatment and novel drug design. Semin Radiat Oncol 8: 176-182.
15. Repnik U, Stoka V, Turk V, Turk B, (2012) Lysosomes and lysosomal cathepsins in cell death. Biochim Biophys Acta 1824: 22-33.
16. Iijima S, Yudasaka M, Yamada R, Bandow S, Suenaga K, et al. (1999) Nano-aggregates of single-walled graphitic carbon nano-horns. Chem Phys Lett 309: 165-170.
17. Huang W, Zhang J, Dorn H, Geohegan D, Zhang C, (2011) Assembly of single-walled carbon nanohorn supported liposome particles. Bioconjugate Chem 22: 1012-1016.
18. Liu J, Stace-Naughton A, Jiang X, Brinker CJ, (2009) Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles. J Am Chem Soc 131: 1354-1355.
19. Ashley CE, Carnes EC, Phillipos GK, Padilla D, Durfee PN, et al. (2011) The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater 10: 389-397.
20. Kasuya D, Yudasaka M, Takahashi K, Kokai F, Iijima S, (2002) Selective production of single-wall carbon nanohorn aggregates and their formation mechanism. J Phys Chem B 106: 4947-4951.
21. Guo W, Johnson JL, Khan S, Ahmad A, Ahmad I, (2005) Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study. Anal Biochem 336: 213-220.
22. Manjappa AS, Chaudhari KR, Venkataraju MP, Dantuluri P, Nanda B, et al. (2011) Antibody derivatization and conjugation strategies: Application in preparation stealth immunoliposome to target chemotherapeutics to tumor. J Control Release 150: 2-22.
23. Jie P, Venkatraman SS, Min F, Chiang Freddy BY, Huat GL, (2005) Micelle-like nanoparticles of starbranched PEO-PLA copolymers as chemotherapeutic carrier. J Control Release 110: 20-33.
24. Cho M, Cho WS, Choi M, Kim SJ, Han BS, et al. (2009) The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles. Toxicol Lett 189: 177-183.
25. Baban DF, Seymour LW, (1998) Control of tumor vascular permeability. Adv Deliv Rev 34: 109-119.
26. Hughes GA, (2005) Nanostructure-mediated drug delivery. Nanomedicine 1: 22-30.
27. He C, Hu Y, Yin L, Tang C, Yin C, (2010) Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31: 3657-3666.
28. Li SD, Huang L, (2009) Nanoparticles evading the reticuloendothelial system: Role of the supported bilayer. Biochim Biophys Acta 1788: 2259-2266.
29. Simoses S, Slepushkin V, Duzgunes N, Lima MCP, (2001) On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes. Biochim Biophys Acta 1515: 23-37.
30. Jones MN, Nicholas AR, (1991) The effect of blood serum on the size and stability of phospholipid liposomes. Biochim Biophys Acta 1065: 145-152.
31. Lasic DD, (1996) Doxorubicin in sterically stabilized liposomes. Nature 380: 561-562.
32. Miyawake J, Yudasaka M, Azami T, Kubo Y, Iijima S, (2008) Toxicity of single-walled carbon nanohorns. ACS Nano 2: 213-226.
33. Lynch RM, Boy BH, Glass DF, Mahurin SM, Zhao B, et al. (2007) Assessing the pulmonary toxicity of single-walled carbon nanohorns. Nanotoxicology 1: 157-166.
34. Constantine P, Firme III MS, Prabhakar RB, (2010) Toxicity issues in the application of carbon nanotubes to biological systems. Nanomedicine 6: 245-256.
35. Extra JM, Cognetti F, Chan S, Maraninchi D, Snyder R,et al. (2003) First-line trastuzumab (Herceptin ®) plus docetaxel versus docetaxel alone in women with HER2-possitive metastatic breast cancer (MBC): results from a randomized phase II trail (M77001). Breast Cancer Res Treat 82:A 217.
36. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
37. Marty M, Cognetti F, Maraninichi D, Snyder R, Mauriac L, et al. (2005) Randomized phase II trail of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administrated as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265-4274.
38. Lammers T, Kiessling F, Hennink WE, Storm G, (2012) Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J Control Release 161: 175-187.
39. Grobmyer SR, Zhou G, Gutwein LG, Iwakuma N, Sharma P, et al. (2012) Nanoparticle delivery for metastatic breast cancer. Maturitas 73: 19-26.
40. Ehrenberg MS, Friedman AE, Finkelstein JN, Oberdorster G, McGrath JL, (2009) The influence of protein adsorption on nanoparticle association with cultured endothelial cells. Biomaterials 30: 603-610.
41. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
42. Dean-Colomb WW, Esteva FJ, (2008) Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 44: 2806-2812.
43. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
44. Hynes NE, Stern DF, (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198: 165-184.
45. Wilcken N, Dear R, (2008) Chemotherapy in metastatic breast cancer: a summary of all randomized trials reported 2000-2007. Eur J Cancer 44: 2218-2225.
46. Puglisi F, Cardoso F, Lerun F, Piccart M, (2006) First-line treatment of metastatic breast cancer: available evidence and current recommendations. Am J Cancer 5: 99-110.
47. Andreetta C, Minisini AM, Miscoria M, Puglisi F, (2010) First-line chemotherapy with or without biologic agents for metastatic breast cancer. Crit Rev Oncol Hematol 76: 99-111.
48. Olayioye MA, Neve RM, Lane HA, Hynes NE, (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167.
49. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, et al. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760.
50. Cirstoiu-Hapca A, Buchegger F, Lange N, Bossy L, Gurny R, et al. (2010) Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice. J Control Release 144: 324-331.
51. Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, et al. (2000) Accelerated blood clearance and altered biodistribution of repeated injections of sterically stablilized liposomes. J Pharmacol Exp Ther 292: 1071-1079.
52. Shu C, Zhang J, Ge J, Sim JH, Brian GB, et al. (2010) A facile high-speed milling method to water-disperse single-walled carbon nanohorns. Chem Mater 22: 347-351.
53. Zhang J, Ge J, Shultz MD, Chung E, Singh G, et al. (2010) In vitro and in vivo studies of single-walled carbon nanohorns with Encapsulated metallofullerenes and exohedrally functionalized quantum dots, Nano Lett. 10: 2843-2848.
54. Sato KT, Larson AC, Rhee TK, Salem RA, Nemcek AA, et al. (2005) Real-time MRI monitoring of transcatheter hepatic artery contrast agent delivery in rabbits. Acad Radiol 12: 1342-1350.